IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM SUSCEPTIBLE TO ANTI-CD47 INDUCED MACROPHAGE PHAGOCYTOSIS VIA NF-KB-TGM2 DRIVEN TUMOR INFLAMMATION

BACKGROUND: While major advances have been made in improving the quality of life and survival of children with most forms of medulloblastoma (MB), those with MYC-driven tumors (Grp3-MB) still suffer significant morbidity and mortality. Here, we report a cross-entity, epigenetic drug screen to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquardt, Viktoria, Theruvath, Johanna, Qin, Nan, Picard, Daniel, Vibhakar, Rajeev, Venkararaman, Sujatha, Remke, Marc, Mitra, Siddhartha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Immunology/Immunotherapy - IMMU
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259949/
http://dx.doi.org/10.1093/neuonc/noad073.194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259949/
http://dx.doi.org/10.1093/neuonc/noad073.194

Ejemplares similares